ES009
ES009 is a high-affinity LILRB2 antagonist, with IC50 values of 14.07 nM and 18.61 nM for inhibiting hLILRB2-huANGPTL3 and hLILRB2-huANGPTL4, respectively. ES009 specifically blocks the interactions between LILRB2 and MHC class I as well as non-MHC ligands, thereby effectively inhibiting receptor activation. ES009 can reprogram anti-inflammatory myeloid cells and induce their conversion to a pro-inflammatory phenotype, and also reverse the T cell suppression mediated by macrophages. When combined with anti-PD-1 blockade therapy, ES009 synergistically enhances T cell activation. ES009 can be used in research related to advanced solid tumors and ovarian cancer.
For research use only. We do not sell to patients.
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Human IgG4 kappa
Human
|
LILRB2 |
ES009 binds to human LILRB2 overexpressed on EL4-huLILRB2 cells, with an EC50 of 0.49 nM[1].
ES009 potently blocks the interactions between human LILRB2 and the MHC class I ligands HLA-G and HLA-A2 on EL4-huLILRB2 cells, with IC50 values of 0.16 nM and 0.24 nM, respectively[1].
ES009 induces a proinflammatory phenotype in human monocyte-derived dendritic cells by blocking LILRB2[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sprague-Dawley (SD) (male and female)[1]
-
Dosage:15 mg/kg; 45 mg/kg; 100 mg/kg; 135 mg/kg; 206 mg/kg
-
Administration:i.v.; single dose
-
Result:Showed no ES009-related adverse effects across all tested doses, including no changes in clinical signs, body weight, food consumption, clinical pathology, immunotoxicity, or histopathology.
Detected no effects on central nervous system function or respiratory system function up to 336 hours post-dose.
Determined the maximum tolerated dose to be 206 mg/kg, the highest feasible dose tested.
LILRB2/ILT4
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
ELISA, FACS, Functional assay
Chemical Information
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
ES009 Related Classifications
HY-P992353 Related Classifications
Powered by Bioz